Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug;11(8):215-225.
doi: 10.1177/1753944717711379. Epub 2017 Jun 22.

Metabolic syndrome: pathophysiology, management, and modulation by natural compounds

Yogita Rochlani  1 , Naga Venkata Pothineni  2 , Swathi Kovelamudi  3 , Jawahar L Mehta  3
Affiliations
Review

Metabolic syndrome: pathophysiology, management, and modulation by natural compounds

Yogita Rochlani et al. Ther Adv Cardiovasc Dis. 2017 Aug.

Abstract

Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that include hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia, and is strongly associated with an increased risk for developing diabetes and atherosclerotic and nonatherosclerotic cardiovascular disease (CVD). The pathogenesis of MetS involves both genetic and acquired factors that contribute to the final pathway of inflammation that leads to CVD. MetS has gained significant importance recently due to the exponential increase in obesity worldwide. Early diagnosis is important in order to employ lifestyle and risk factor modification. Here, we review the epidemiology and pathogenesis of MetS, the role of inflammation in MetS, and summarize existing natural therapies for MetS.

Keywords: atherogenic dyslipidemia; cardiovascular disease; hypertension; insulin resistance; metabolic syndrome; nutraceuticals; obesity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Figures

Figure 1.
Figure 1.
Pathophysiological mechanisms in metabolic syndrome. AT2, angiotensin II type 2 receptor; CRP, C-reactive protein; IL-6, interleukin 6; LOX, lectin-like oxidized low-density lipoprotein; RAAS, renin-angiotensin-aldosterone system; ROS, reactive oxygen species; TNF, tumor necrosis factor.
See this image and copyright information in PMC

References

    1. Grundy SM, Hansen B, Smith SC, Jr, et al. American Heart Association, National Heart, Lung, and Blood Institute, American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004; 24(2): e19–e24. - PubMed
    1. Beltrán-Sánchez H, Harhay MO, Harhay MM, et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol 2013; 62(8): 697–703. - PMC - PubMed
    1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356–359. - PubMed
    1. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28(4): 629–636. - PubMed
    1. Miller JM, Kaylor MB, Johannsson M, et al. Prevalence of metabolic syndrome and individual criterion in US adolescents: 2001–2010 National Health and Nutrition Examination Survey. Metab Syndr Relat Disord 2014; 12(10): 527–532. - PubMed

MeSH terms

Substances